We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanoparticle Delivery of Drug Combination Blocks Pancreatic Cancer Growth in Mouse Model

By LabMedica International staff writers
Posted on 06 Apr 2015
Print article
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
Image: TEM (transmission electron micrograph) of a mesoporous silica nanoparticle (Photo courtesy of Wikimedia Commons).
Cancer researchers using two potent chemotherapeutic agents combined in one nanoparticle demonstrated significant improvement in the treatment of pancreatic tumors in a mouse model.

The current frontline method for treatment of pancreatic cancer is a combination of gemcitabine and Abraxane. Gemcitabine is a pyrimidine antimetabolite that interferes with the metabolism and growth of cells by replacing the pyrimidine deoxycytidine in DNA, thereby preventing the DNA from being manufactured or repaired. As a result, cells cannot reproduce and eventually die. Abraxane is nanoparticle albumin-bound form of paclitaxel, a chemotherapy agent made from the needles and bark of certain kinds of yew trees that is used to treat breast cancer. Paclitaxel improves the pharmaceutical efficacy of gemcitabine through suppression of the tumor stroma and inhibiting the expression of the gemcitabine-inactivating enzyme, cytidine deaminase (CDA). Gemcitabine and Abraxane are administered separately, which works to a certain extent, but as the drugs have different half-lives in the body, the combined beneficial effect is not fully synchronized.

Investigators at the University of California, Los Angeles (UCLA; USA) asked whether it would be possible to develop a mesoporous (containing pores with diameters between two and 50 nanometers) silica nanoparticle (MSNP) carrier to co-deliver a synergistic gemcitabine/paclitaxel combination to pancreatic cancer cells.

High drug loading was achieved by a custom-designed coated lipid film technique to encapsulate a calculated dose of gemcitabine (40% by weight) by using a supported lipid bilayer (LB). The uniform coating of the 65 nanometer nanoparticles by a lipid membrane allowed incorporation of a sub-lethal amount of hydrophobic paclitaxel, which could be co-delivered with gemcitabine to pancreatic cells and tumors.

To demonstrate the in vivo efficacy of the nanoparticle delivery system, mice carrying subcutaneous PANC-1 xenografts received intravenous (IV) injection of paclitaxel-gemcitabine loaded nanoparticles. Results published in the March 16, 2015, online edition of the journal ACS Nano showed that drug co-delivery provided more effective tumor shrinkage than gemcitabine loaded nanoparticles, free gemcitabine, or free gemcitabine plus Abraxane. Comparable tumor shrinkage required co-administration of 12 times the amount of free Abraxane.

HPLC (high pressure liquid chromatograph) analysis of tumor-associated gemcitabine metabolites confirmed that, compared to free gemcitabine, nanoparticle co-delivery increased the phosphorylated, DNA-interactive gemcitabine metabolite 13-fold, while decreasing the inactivated, deaminated metabolite four-fold. IV injection of nanoparticle-delivered gemcitabine/paclitaxel in a PANC-1 orthotropic model effectively inhibited primary tumor growth as well as eliminating metastatic foci. The enhanced in vivo efficacy of the dual delivery carrier could be achieved with no evidence of local or systemic toxicity.

“Instead of just a laboratory proof-of-principle study of any cancer, we specifically attacked pancreatic cancer with a custom-designed nanocarrier,” said senior author Dr. Andre Nel, professor of medicine at UCLA. “In our platform, the drugs are truly synergistic because we have control over drug mixing, allowing us to incorporate optimal ratios in our particles, making the relevance of our models very high and our results very strong.”

Related Links:

University of California, Los Angeles


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.